Meningococcal Groups ACYW135 and Haemophilus b Conjugate Vaccine (Walvax Biotechnology)

ACYW135群脑膜炎球菌-b型流感嗜血杆菌多糖结合疫苗（沃森生物）

Report date: 2022/03/04 20:00:41

Base Information

Drug NameMeningococcal Groups ACYW135 and Haemophilus b Conjugate Vaccine (Walvax Biotechnology)
Drug Alias NameN/A
ClassificationVaccines > Biological material > Bacterial vaccineVaccines > Development/production technology > Conjugated vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsEncephalomyelitisMeningococcal InfectionsMeningitis, Meningococcal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesWalvax Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWalvax Biotechnology Co LtdYuxi Walvax Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsEncephalomyelitisMeningitis, Meningococcal
Inactive IndicationsMeningococcal Infections

Other Information

ATC CodeN/A
Related LinksN/A